Evidence map›Paper›PMID 40475670›Full record

ArticlebioRxiv : the preprint server for biology2025

Mutation rate variability in viral populations: implications for lethal mutagenesis.

Sarah Arcos, Adam S Lauring

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sarah ArcosDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor.ORCID 0000-0002-3003-9040
Adam S LauringDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor.ORCID 0000-0003-2906-8335

Funding

Functional and genetic constraints on influenza virus replication and fidelityR01AI170520 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAURING, ADAM · 2022 to 2025
$2.4M
NIAID NIH HHS R01 AI170520
6 · The paper itself

Abstract

Lethal mutagenesis is a strategy to achieve viral extinction by drugging viral mutation rates beyond an extinction threshold. Accurate estimation of the extinction threshold is critical, as elevating viral mutation rates near, but not past this threshold increases the likelihood of mutations that could result in drug resistance, vaccine escape, or increased pathogenesis. Traditional models of lethal mutagenesis rely on the Poisson distribution, which assumes a uniform mutation rate across individuals. Yet, RNA viruses like influenza A virus (IAV) can have varied mutation rates due to mutations in the polymerase complex. This variability suggests that lethal mutagenesis models incorporating mutation rate diversity, such as ones using the gamma-Poisson distribution, may be more accurate for RNA viruses. Poisson models assume count data have equal mean and variance, while gamma-Poisson counts are overdispersed (variance greater than mean). Here we provide experimental data showing that IAV mutations are overdispersed, indicating that the gamma-Poisson distribution is more appropriate for modeling IAV mutations. Modeling of lethal mutagenesis using the gamma-Poisson distribution reveals that the degree of overdispersion is critical in determining survival or extinction. Increased overdispersion shifts the extinction threshold higher, indicating that Poisson-based models have underestimated the mutation rate required to achieve viral extinction and avoid viral escape or accelerated evolution. Furthermore, time to extinction in simulated populations is significantly longer with gamma-Poisson-based models than Poisson-based. This investigation of how mutation rate variability affects lethal mutagenesis will directly impact antiviral drug design and strategy, thus advancing efforts to combat virus outbreaks and future pandemics.

Indexed as

Biological SciencesevolutionEvolutionlethal mutagenesismutation ratesRNA virus

Identifiers

PMID40475670
PMCPMC12139918

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.